Health & Fitness
Health and Fitness
Health and Fitness
Wed, December 17, 2008
Tue, December 16, 2008 Myriad Genetics: Myriad Genetics, Inc. Receives Approval From New York Stock Exchange to Proceed With New Listing
SALT LAKE CITY, UT--(Marketwire - December 16, 2008) - Myriad Genetics, Inc. (
"We welcome Myriad Genetics to the New York Stock Exchange," said Duncan Niederauer, CEO of NYSE Euronext. "Since 1991, Myriad Genetics has grown as a world leader in the field of molecular diagnostics, working to assess an individual's risk of developing disease later in life and assuring that a patient's treatment is efficacious and well tolerated as determined by their genetic makeup. We applaud the work of Myriad Genetics, and look forward to a successful partnership. NYSE Euronext is committed to providing the company and its shareholders the highest levels of market quality and service."
"We are proud to partner with the New York Stock Exchange and join the many fine companies listed under the NYSE Euronext global umbrella. This is a milestone in our corporate history. With Myriad Genetics' expanding reach and enhanced molecular diagnostic focus, we are confident our shareholders will be well served by the NYSE's outstanding service, trading efficiencies and global brand strength," said Peter D. Meldrum, President & CEO of Myriad Genetics, Inc.
Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of novel therapeutic and molecular diagnostic products. Myriad's news and other information are available on the Company's Web site at [ www.myriad.com ].
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's anticipation of trading on the NYSE Big Board in the second calendar quarter of 2009 and that the Company's stock will trade under the new ticker symbol "MGX." These forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, our inability to further identify, develop and achieve commercial success for new products and technologies; our ability to discover drugs that are safer and more efficacious than our competitors; our ability to develop additional molecular diagnostic products that help assess which patients are subject to greater risk of developing diseases and who would therefore benefit from new preventive therapies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; our ability to protect our proprietary technologies; patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2008, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
